SHOWNOTES

This week on Telltales, Hunt, Mike, and Jason break down the most consequential disruption to global energy markets in decades — the effective closure of the Strait of Hormuz — and what it means for oil prices, capital markets, and portfolio positioning. The conversation then pivots to AI agents, harness engineering, and the structural shift in how companies will operate.

[00:00] **Strait of Hormuz Closure and Oil Market Impact**

Hunt walks through the mechanics of losing ~20 million barrels of daily transit through Hormuz, the Israeli strike on Iran’s Pars gas facility, and Iran’s threatened retaliation against Saudi, UAE, and Qatari infrastructure. Near-month crude has moved from $60 pre-conflict to $100, with October $120 calls trading at $2.

[03:16] **Scenarios for Oil Price Resolution**

Could a ceasefire or Iranian-controlled transit regime bring prices back toward $80? Hunt outlines the pipeline alternatives — Red Sea, Fujairah, Turkey — and what a partial normalization by Q4 might look like. The consensus: $60 oil is gone for the foreseeable future.

[06:16] **Why This Wasn’t a War of Choice**

Jason and Hunt argue the Iran conflict was inevitable given the nuclear trajectory, with Iran’s stated objectives making a deal structurally impossible. The military campaign has been more decisive than expected, but drone suppression remains the key challenge.

[09:50] **Exhibit B: Natural Gas Supply Problem**

Permian associated gas continues to flood the market at 24 Bcf/day, with hub prices negative. New pipeline capacity (up to 5 Bcf/day) is coming but won’t arrive until late 2026. Higher oil activity will only worsen the gas oversupply.

[11:07] **Exhibit A: US Government Fiscal Outlook**

Healthcare spending is the main lever. Medicare and Medicaid may flatten with Trump administration changes. The US is improving directionally versus China, Japan, and Europe. The Fed holds rates steady.

[14:00] **Mag Seven Resilience and AI CapEx Justification**

Despite geopolitical turmoil, the Mag Seven remain remarkably steady at 40% of the index. Hunt, Mike, and Jason argue the AI infrastructure buildout is justified — each new chip generation is ~10x more efficient, breaking the typical industrial capacity cycle.

[17:01] **Capital Returns and Why This Cycle Is Different**

Mike draws on Edward Chancellor’s Capital Returns framework: unlike concrete plants, new GPU capacity is 90% more efficient than what it replaces. Token consumption is scaling with problem complexity, and Jensen Huang’s GTC keynote framed token budgets as the new employee benefit.

[19:42] **AI Impact on Healthcare and Pharma R&D**

Jason sees pharma companies testing more molecules rather than cutting headcount. The biggest efficiency gain: regulatory filing assembly for FDA submissions. Net effect is more drugs in the pipeline, which is positive for patients.

[23:09] **Agents: From Open Claw to 2 Billion Users**

The team debates agent adoption. Jason predicts every iPhone becomes an agent within a year — the orchestration runs on-device while inference runs in the cloud. Apple’s Siri delays leave the door open for Anthropic, OpenAI, and Google.

[25:24] **Harness Engineering: The Next Software Layer**

Mike defines the emerging discipline: writing traditional software that feeds the right context to LLMs at the right time. From Cursor to Claude Code to Open Claw, the pattern is vertical tools designed for specific jobs. Companies will reorganize around people + AI with tools and skills.

[29:39] **Diagnostics, GLP-1s, and Bending the Healthcare Cost Curve**

The path to lower healthcare costs runs through cheaper diagnostics (blood draws, genomics, AI symptom analysis) gating access to specialists, plus long-term benefits from GLP-1 adoption reducing total system burden.

Download the full Cash Flow Memo with updated financials for ~80 companies at telltales.us. New episodes every Wednesday.

This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com